Moderna (MRNA) to Supply an 20M Doses of COVID-19 Vaccine to COVAX for 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022
December 10, 2021 9:00 AM ESTTotal of 54 million doses to be supplied to COVAX in 2021
New 2022 supply agreement: 20 million additional doses purchased for supply in Q2 for total of 136.5 million doses; Gavi retains option for additional 30 million in Q2 and 100 million in Q3 2022
Gavi now retains the option to procure a total of up to 650 million doses in 2021 and 2022
CAMBRIDGE, Mass.--(BUSINESS... More
